3 Reasons to Avoid MYGN and One Alternative Stock Worth Buying

Myriad Genetics: Recent Performance and Investor Considerations

Over the past half-year, Myriad Genetics shareholders have faced significant losses, with the stock tumbling 31.8% to its current price of $5.24. This sharp decline has left many investors questioning their next move.

Should you consider adding Myriad Genetics to your portfolio, or is caution warranted?

Why We Believe Myriad Genetics May Continue to Lag

Although the stock's lower price might seem attractive, we remain hesitant about Myriad Genetics at this time. Below are three key reasons for our cautious stance, along with an alternative stock we prefer.

1. Slowing Revenue Expansion

At StockStory, we prioritize sustainable growth. In the healthcare sector, focusing solely on long-term trends can sometimes overlook recent industry shifts. Myriad Genetics has experienced a slowdown in demand, with annualized revenue growth of just 4.6% over the past two years—falling short of its five-year average. Such deceleration in revenue can indicate evolving consumer preferences and the ease with which customers can switch providers.

2. Past Expansion Efforts Have Been Unprofitable

While growth is important, it's equally vital to assess how efficiently that growth is achieved. Return on invested capital (ROIC) measures how much operating profit a company generates relative to the capital it has raised. Over the last five years, Myriad Genetics posted an average ROIC of negative 34.3%, indicating that expansion efforts have resulted in substantial losses—among the poorest returns in the healthcare industry.

3. Declining Returns from New Investments

ROIC is a key indicator of a company's ability to generate profits from its investments. We typically favor businesses with strong and improving returns. However, Myriad Genetics has seen its ROIC deteriorate further in recent years. Combined with already weak returns, this downward trend suggests that the company is struggling to find lucrative growth opportunities.

Our Verdict

Myriad Genetics does not meet our standards for quality investments. After its recent drop, the stock is trading at a forward P/E ratio of 70.7 (or $5.24 per share), which implies that much optimism is already priced in. We believe there are more compelling opportunities elsewhere. For example, consider a rapidly expanding restaurant chain known for its top-rated ranch dressing.

Stocks We Prefer Over Myriad Genetics

ALSO RECOMMENDED: Top 5 Momentum Stocks. The ideal moment to invest in a standout stock is when the market starts to recognize its potential. These companies not only have robust fundamentals but are also experiencing strong momentum right now—a rare and valuable combination.

Discover which stocks our AI-driven platform is highlighting this week. Explore the latest Strong Momentum stocks for free.

Our selections have included well-known names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Comfort Systems, which delivered a 782% return over five years. Start your search for the next breakout stock with StockStory today.